|
Active substance |
tucatinib (ONT-380) |
|
Holder |
Seagen |
|
Status |
closed |
|
Indication |
in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2 positive locally advanced or metastatic breast cancer who have received at least 2 prior anti HER2 treatment regimens. |
|
Public documents |
|
|
Last update |
19/04/2024 |
Tukysa®
Last updated on 13/09/2024